ACTRN12622001063707招募中未知
BEAT CF: Pulmonary Exacerbations Treatment Platform - Adjunct Antibiotics Domain:An evaluation of the comparative effectiveness of prescribing various standard of care, adjunct Antibiotics in the management of pulmonary exacerbations requiring intensive therapy (PERIT) in children and adults with CF, with respect to their short-term improvement in lung function.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 5 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Be enrolled in the BEAT CF PEx Cohort (ACTRN12621000638831).
- •2. Documented informed consent to participate in the Adjunct antibiotic Domain.
- •3. Are eligible for at least two Interventions in the Adjunct Antibiotic Domain available at the clinical Site (including no Adjunct Antibiotic).
- •4. Must be able to reliably perform spirometry.
排除标准
- •1. The person is unable to reliably perform spirometry (for example due to young age)
- •2. The person’s Responsible Clinician deems enrolment in the PEx Adjunct Antibiotic Domain is not in their best interest.
- •A participant will be excluded from Assignment to a specific Intervention in the Adjunct Antibiotic Domain if:
- •1. They have a known or suspected significant drug hypersensitivity to tobramycin or other aminoglycosides
- •2. Recognised contraindication to IV tobramycin, including known renal, auditory or vestibular impairment which, in the opinion of the Responsible Clinician, precludes its use.
- •3. The Intervention is deemed unacceptable by the Responsible Clinician e.g. because of a poor treatment response to that antibiotic (requiring a change in antibiotic treatment) in the preceding 12 months
研究者
相似试验
招募中
不适用
BEAT CF: Pulmonary Exacerbations Treatment Platform - Backbone Antibiotics DomaiCystic FibrosisACTRN12622000950763niversity of Sydney500
进行中（未招募）
1 期
Therapy of lungs of CF-patients with Amitriptyline - a randomised, double-blind, placebo-controlled cohort trialAmitriptyline reduces ceramide concentrations in bronchial epithelial cells and reduces cell death and reduces the deposition of DNA on the respiratory epithelium. This reduction promotes the elimination of P. aeruginosa bacteria from the lung. As a result, treatment normalizes inflammation in CF lungs. Amitriptyline thus reduces systemic and local inflammation. Because of these effects, amitriptyline increases lung function in CF patients.EUCTR2014-003581-25-DEniversity Hospital Tuebingen102
进行中（未招募）
1 期
Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and PlaceboEUCTR2008-002673-13-DEPSKS
已完成
4 期
Standardized Treatment of Pulmonary Exacerbations IIPulmonary Cystic FibrosisNCT02781610Chris Goss982
Unknown
2 期
Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis PatientsSymptomatic BronchiectasisNCT01580748Seoul National University Bundang Hospital25